VolitionRx Limited (NYSE American: VNRX) has entered into a collaboration with Sysmex (TYO: 6869) to optimize the company’s Nu.Q® NETs H3.1 assay on Sysmex’s diagnostic platform, according to a press release. The agreement aligns with Volition’s strategy of licensing its proprietary Nu.Q® NETs technology to established global diagnostics companies, leveraging their disease expertise, regulatory capabilities, and installed analyzer base to accelerate development and commercialization.
The collaboration has progressed beyond assay transfer and is now in the optimization phase for diseases associated with NETosis, a process implicated in conditions including sepsis and other acute and chronic diseases. The company believes the Nu.Q® NETs assay could provide improved diagnostic information, support patient monitoring, and address a commercial opportunity with an estimated total addressable market of $3.8 billion.
Volition is a multinational company focused on advancing the science of epigenetics, dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients but also to improve their quality of life.
The company’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. For further information, visit the company’s website at https://volition.com/.
To view the full press release, visit https://ibn.fm/TSMG4.
